Xinhua Bio completed tens of millions of US dollars in Series A financing
August 29, 2025
Source: drugdu
82
On August 25th, Xinhua Bio announced the completion of a multi-million dollar Series A financing round. The Series A+ round was led by Xingze Capital, while the Series A round was led by Sany Innovation Investment, with participation from other existing shareholders, including Sequoia China. The funds will be primarily used to advance the company's core pipeline into global clinical trials, accelerate research and development, and provide more effective treatment options for patients worldwide.
Comment: Xinhua Biopharma received tens of millions of US dollars in Series A financing. The funds will help its core pipeline enter global clinical trials, accelerate research and development, and highlight its research and development potential and market value in fields such as tumor immunology.
https://finance.eastmoney.com/a/202508273495486977.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
